The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000
lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes
mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with
limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19.
HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and
exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin
and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate
use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic
agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications
to the use of this drug.
Keywords: HCQ, diabetes mellitus, COVID-19, T2DM, vaccine, pandemic, SARS-CoV-2.
Rights & PermissionsPrintExport